JP2010526995A - 結腸直腸癌のマーカーとしてのｔｉｍｐ−１の使用 - Google Patents
結腸直腸癌のマーカーとしてのｔｉｍｐ−１の使用 Download PDFInfo
- Publication number
- JP2010526995A JP2010526995A JP2010506846A JP2010506846A JP2010526995A JP 2010526995 A JP2010526995 A JP 2010526995A JP 2010506846 A JP2010506846 A JP 2010506846A JP 2010506846 A JP2010506846 A JP 2010506846A JP 2010526995 A JP2010526995 A JP 2010526995A
- Authority
- JP
- Japan
- Prior art keywords
- timp
- stool
- colorectal cancer
- marker
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010009944 Colon cancer Diseases 0.000 title claims abstract description 130
- 239000003550 marker Substances 0.000 title claims abstract description 63
- 208000001333 Colorectal Neoplasms Diseases 0.000 title claims abstract description 56
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 title claims 9
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 title claims 9
- 238000003745 diagnosis Methods 0.000 claims abstract description 35
- 238000000034 method Methods 0.000 claims abstract description 29
- 206010028980 Neoplasm Diseases 0.000 claims description 54
- 239000011230 binding agent Substances 0.000 claims description 39
- 108010054147 Hemoglobins Proteins 0.000 claims description 33
- 102000001554 Hemoglobins Human genes 0.000 claims description 33
- 102000001109 Leukocyte L1 Antigen Complex Human genes 0.000 claims description 17
- 108010069316 Leukocyte L1 Antigen Complex Proteins 0.000 claims description 17
- 239000011536 extraction buffer Substances 0.000 claims description 17
- 230000009870 specific binding Effects 0.000 claims description 17
- 230000015572 biosynthetic process Effects 0.000 claims description 10
- 102000014702 Haptoglobin Human genes 0.000 claims description 9
- 108050005077 Haptoglobin Proteins 0.000 claims description 9
- 102000013009 Pyruvate Kinase Human genes 0.000 claims description 6
- 108020005115 Pyruvate Kinase Proteins 0.000 claims description 6
- 230000027455 binding Effects 0.000 claims description 5
- 238000013399 early diagnosis Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 238000001514 detection method Methods 0.000 abstract description 29
- 238000005259 measurement Methods 0.000 abstract description 28
- 108090000623 proteins and genes Proteins 0.000 abstract description 24
- 102000004169 proteins and genes Human genes 0.000 abstract description 23
- 108010005246 Tissue Inhibitor of Metalloproteinases Proteins 0.000 abstract description 3
- 102000005876 Tissue Inhibitor of Metalloproteinases Human genes 0.000 abstract description 3
- 239000000523 sample Substances 0.000 description 93
- 238000003556 assay Methods 0.000 description 32
- 201000011510 cancer Diseases 0.000 description 31
- 230000035945 sensitivity Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 16
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 15
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 15
- 238000012216 screening Methods 0.000 description 14
- 201000010099 disease Diseases 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 239000000284 extract Substances 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 102000012406 Carcinoembryonic Antigen Human genes 0.000 description 11
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 11
- 238000000605 extraction Methods 0.000 description 11
- 238000003018 immunoassay Methods 0.000 description 11
- 241000147041 Guaiacum officinale Species 0.000 description 10
- 229940091561 guaiac Drugs 0.000 description 10
- 238000005070 sampling Methods 0.000 description 10
- 239000012491 analyte Substances 0.000 description 9
- 238000002405 diagnostic procedure Methods 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- 238000002052 colonoscopy Methods 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 7
- 210000002381 plasma Anatomy 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 206010027476 Metastases Diseases 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 210000001072 colon Anatomy 0.000 description 5
- 108010071602 haptoglobin-hemoglobin complex Proteins 0.000 description 5
- 230000003211 malignant effect Effects 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical group O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 4
- 208000003200 Adenoma Diseases 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 239000000090 biomarker Substances 0.000 description 4
- 238000009826 distribution Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000002550 fecal effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 230000004083 survival effect Effects 0.000 description 4
- 206010001233 Adenoma benign Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 3
- 206010061309 Neoplasm progression Diseases 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000009534 blood test Methods 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002738 chelating agent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000002596 correlated effect Effects 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 238000007423 screening assay Methods 0.000 description 3
- 238000012549 training Methods 0.000 description 3
- 230000005751 tumor progression Effects 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 2
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 2
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000002820 assay format Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002744 extracellular matrix Anatomy 0.000 description 2
- 230000002349 favourable effect Effects 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 238000009533 lab test Methods 0.000 description 2
- 238000007477 logistic regression Methods 0.000 description 2
- 238000002824 mRNA display Methods 0.000 description 2
- 230000009401 metastasis Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000005180 public health Effects 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- FXNDIJDIPNCZQJ-UHFFFAOYSA-N 2,4,4-trimethylpent-1-ene Chemical compound CC(=C)CC(C)(C)C FXNDIJDIPNCZQJ-UHFFFAOYSA-N 0.000 description 1
- 108091023037 Aptamer Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 description 1
- 108050003489 DNA replication licensing factor Mcm2 Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 description 1
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108010044467 Isoenzymes Proteins 0.000 description 1
- 102000004856 Lectins Human genes 0.000 description 1
- 108090001090 Lectins Proteins 0.000 description 1
- -1 M2-PK Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 102100026262 Metalloproteinase inhibitor 2 Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000008297 Nuclear Matrix-Associated Proteins Human genes 0.000 description 1
- 108010035916 Nuclear Matrix-Associated Proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 208000037062 Polyps Diseases 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 102100032442 Protein S100-A8 Human genes 0.000 description 1
- 102100032420 Protein S100-A9 Human genes 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 108010031372 Tissue Inhibitor of Metalloproteinase-2 Proteins 0.000 description 1
- 206010064390 Tumour invasion Diseases 0.000 description 1
- 208000037842 advanced-stage tumor Diseases 0.000 description 1
- 210000004381 amniotic fluid Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000002790 cross-validation Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000001839 endoscopy Methods 0.000 description 1
- 230000007515 enzymatic degradation Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000008571 general function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010036302 hemoglobin AS Proteins 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000002523 lectin Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- MGFYIUFZLHCRTH-UHFFFAOYSA-N nitrilotriacetic acid Chemical compound OC(=O)CN(CC(O)=O)CC(O)=O MGFYIUFZLHCRTH-UHFFFAOYSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008354 tissue degradation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000000504 visceral peritoneum Anatomy 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/81—Protease inhibitors
- G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07009396 | 2007-05-10 | ||
| PCT/EP2008/003642 WO2008138522A1 (en) | 2007-05-10 | 2008-05-07 | Use of timp-1 as a marker for colorectal cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010526995A true JP2010526995A (ja) | 2010-08-05 |
| JP2010526995A5 JP2010526995A5 (cg-RX-API-DMAC7.html) | 2011-02-17 |
Family
ID=38521224
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010506846A Withdrawn JP2010526995A (ja) | 2007-05-10 | 2008-05-07 | 結腸直腸癌のマーカーとしてのｔｉｍｐ−１の使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20100159479A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2145190A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2010526995A (cg-RX-API-DMAC7.html) |
| CN (1) | CN101680898A (cg-RX-API-DMAC7.html) |
| CA (1) | CA2684024A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2008138522A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009065551A1 (en) * | 2007-11-20 | 2009-05-28 | Roche Diagnostics Gmbh | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex |
| EP2239577A1 (en) * | 2009-04-07 | 2010-10-13 | Vereniging voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek en Patiëntenzorg | Protein-based methods and compositions for the diagnosis of colorectal adenocarcinoma |
| US20130345322A1 (en) * | 2010-07-14 | 2013-12-26 | Commonwealth Scientific And Industrial Research Organisation | Diagnostic for colorectal cancer |
| EP3000897B1 (en) * | 2013-05-21 | 2019-10-16 | Biomérieux | Colorectal cancer prognosis agent kit |
| EP3073268A1 (en) * | 2015-03-27 | 2016-09-28 | Deutsches Krebsforschungszentrum Stiftung des Öffentlichen Rechts | Biomarker panel for diagnosing cancer |
| CN105891372B (zh) * | 2016-06-12 | 2018-11-02 | 上海阿趣生物科技有限公司 | 原发性肝癌伴胆管癌栓生物标志物及其用途 |
| CN113122544A (zh) * | 2021-04-25 | 2021-07-16 | 杭州广科安德生物科技有限公司 | 一种特异性结合timp1蛋白的核酸适配体及其应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5324636A (en) * | 1991-07-24 | 1994-06-28 | The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon Health Sciences University | Radiorespirometer and method of use |
| US5455160A (en) * | 1993-05-27 | 1995-10-03 | Fagerhol; Magne K. | Diagnostic test and kit for disease or disorders in the digestive system |
| AU2681997A (en) * | 1996-04-26 | 1997-11-19 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
| WO2000062070A2 (en) * | 1999-04-09 | 2000-10-19 | Rigshospitalet | Tissue inhibitor of matrix metalloproteinases type-1 (timp-1) as a cancer marker |
| US7374886B2 (en) * | 1999-04-09 | 2008-05-20 | Rigshospitalet | Tissue inhibitor of matrix metalloproteinases type-1 (TIMP-1) as a cancer marker and postoperative marker for minimal residual disease or recurrent disease in patients with a prior history of cancer |
| WO2002031507A2 (en) * | 2000-10-13 | 2002-04-18 | Children's Medical Center Corporation | Non-invasive enzyme screen for tissue remodelling-associated conditions |
| WO2005095978A1 (en) * | 2004-03-30 | 2005-10-13 | Roche Diagnostics Gmbh | Pyrroline-5-carboxylate reductase as a marker for colorectal concer |
| FR2919065B1 (fr) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage de l'apolipoproteine ai pour le diagnostic in vitro du cancer colorectal |
| FR2919063B1 (fr) * | 2007-07-19 | 2009-10-02 | Biomerieux Sa | Procede de dosage du leucocyte elastase inhibitor pour le diagnostic in vitro du cancer colorectal. |
-
2008
- 2008-05-07 JP JP2010506846A patent/JP2010526995A/ja not_active Withdrawn
- 2008-05-07 EP EP08758392A patent/EP2145190A1/en not_active Withdrawn
- 2008-05-07 CA CA002684024A patent/CA2684024A1/en not_active Abandoned
- 2008-05-07 WO PCT/EP2008/003642 patent/WO2008138522A1/en not_active Ceased
- 2008-05-07 CN CN200880015574A patent/CN101680898A/zh active Pending
-
2009
- 2009-11-06 US US12/613,760 patent/US20100159479A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN101680898A (zh) | 2010-03-24 |
| US20100159479A1 (en) | 2010-06-24 |
| CA2684024A1 (en) | 2008-11-20 |
| WO2008138522A1 (en) | 2008-11-20 |
| EP2145190A1 (en) | 2010-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2021794B1 (en) | Use of protein s100a 12 as a marker for colorectal cancer | |
| ES2527649T3 (es) | Panel de marcadores para el cáncer colorrectal | |
| CA2701341C (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| US20080064047A1 (en) | Methods for diagnosis and prognosis of epithelial cancers | |
| CA2629071A1 (en) | Method of assessing colorectal cancer by measuring hemoglobin and m2-pk in a stool sample | |
| US20100159479A1 (en) | Timp-1 as a marker for colorectal cancer | |
| CN108369233B (zh) | 基于标志物人附睾蛋白4 (he4)检测肺腺癌的复发的方法及相关用途 | |
| US20220390453A1 (en) | Ovarian cancer biomarker and methods of using same | |
| HK1142130A (en) | Use of timp-1 as a marker for colorectal cancer | |
| CA3163199A1 (en) | Ovarian cancer biomarker and methods of using same | |
| HK1149956B (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101221 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101221 |
|
| A761 | Written withdrawal of application |
Free format text: JAPANESE INTERMEDIATE CODE: A761 Effective date: 20120118 |